Endocrinology, Vol 136, 866-872, Copyright © 1995 by Endocrine Society

ARTICLES

Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060

C Mathieu, M Waer, K Casteels, J Laureys and R Bouillon
Laboratory for Experimental Medicine and Endocrinology, Catholic University of Leuven, Belgium.

Pharmacological amounts of 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] have potent immunoregulatory activity, but with marked effects on calcium and bone metabolism. In this study we demonstrate that nonhypercalcemia- inducing nondemineralizing doses of an analog of 1,25-(OH)2D3, 1 alpha,25-(OH)2-20-epi-22-oxa-24,26,27-trishomo-vitamin D (KH1060), can prevent type I diabetes. Female NOD mice received 1,25-(OH)2D3 (5 micrograms/kg), KH1060 (0.4 or 0.2 micrograms/kg), or the treatment vehicle ip every 2 days from 21-200 days of age. The incidence of diabetes in controls was 17 of 31 (55%), whereas 7 of 38 (18%) 1,25- (OH)2D3-treated mice, 3 of 27 (11%) KH1060 (0.4 micrograms/kg)-treated mice, and 6 of 27 (22%) KH1060 (0.2 micrograms/kg)-treated mice developed diabetes (P < 0.025 vs. controls). Protection was achieved with the low KH1060 dose without effects on calcium or bone metabolism, as evaluated by serum calcium (9.5 +/- 0.4 vs. 9.4 +/- 0.3 mg/dl in controls; P = NS), serum osteocalcin (82 +/- 17 vs. 83 +/- 20 ng/ml; P = NS), bone calcium content (6.8 +/- 0.7 vs. 6.4 +/- 0.5 mg/tibia; P = NS), urinary calcium (21 +/- 4 vs. 21 +/- 4 mg/dl; P = NS), pyridinoline excretion, and duodenal calbindin-D9K concentration. The proposed mechanism of action is a restoration of suppressor cell activity, as demonstrated in vitro (suppressor cell assay) and in vivo (cell transfer experiments). This study demonstrates that an analog of 1,25-(OH)2D3 prevents type I diabetes in NOD mice without significant effects on calcium or bone metabolism.

This article has been cited by other articles:

				J B. Richards, A. M Valdes, J. P Gardner, D. Paximadas, M. Kimura, A. Nessa, X. Lu, G. L Surdulescu, R. Swaminathan, T. D Spector, et al. Higher serum vitamin D concentrations are associated with longer leukocyte telomere length in women Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1420 - 1425. [Abstract] [Full Text] [PDF]

				G. E. Mullin and A. Dobs Vitamin D and Its Role in Cancer and Immunity: A Prescription for Sunlight Nutr Clin Pract, June 1, 2007; 22(3): 305 - 322. [Abstract] [Full Text] [PDF]

				J. Sun, J. Kong, Y. Duan, F. L. Szeto, A. Liao, J. L. Madara, and Y. C. Li Increased NF-{kappa}B activity in fibroblasts lacking the vitamin D receptor Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E315 - E322. [Abstract] [Full Text] [PDF]

				S. Nagpal, S. Na, and R. Rathnachalam Noncalcemic Actions of Vitamin D Receptor Ligands Endocr. Rev., August 1, 2005; 26(5): 662 - 687. [Abstract] [Full Text] [PDF]

				C. A. Gysemans, A. K. Cardozo, H. Callewaert, A. Giulietti, L. Hulshagen, R. Bouillon, D. L. Eizirik, and C. Mathieu 1,25-Dihydroxyvitamin D3 Modulates Expression of Chemokines and Cytokines in Pancreatic Islets: Implications for Prevention of Diabetes in Nonobese Diabetic Mice Endocrinology, April 1, 2005; 146(4): 1956 - 1964. [Abstract] [Full Text] [PDF]

				N. Giarratana, G. Penna, S. Amuchastegui, R. Mariani, K. C. Daniel, and L. Adorini A Vitamin D Analog Down-Regulates Proinflammatory Chemokine Production by Pancreatic Islets Inhibiting T Cell Recruitment and Type 1 Diabetes Development J. Immunol., August 15, 2004; 173(4): 2280 - 2287. [Abstract] [Full Text] [PDF]

				A. J. Brown, A. Dusso, and E. Slatopolsky Vitamin D Am J Physiol Renal Physiol, August 1, 1999; 277(2): F157 - F175. [Abstract] [Full Text] [PDF]

				S. J Smith, M. E Hayes, P. L Selby, and E B. Mawer Autocrine control of vitamin D metabolism in synovial cells from arthritic patients Ann Rheum Dis, June 1, 1999; 58(6): 372 - 378. [Abstract] [Full Text]

				K. M. Casteels, C. Mathieu, M. Waer, D. Valckx, L. Overbergh, J. M. Laureys, and R. Bouillon Prevention of Type I Diabetes in Nonobese Diabetic Mice by Late Intervention with Nonhypercalcemic Analogs of 1,25-Dihydroxyvitamin D3 in Combination with a Short Induction Course of Cyclosporin A Endocrinology, January 1, 1998; 139(1): 95 - 102. [Abstract] [Full Text] [PDF]

				T. M. Nguyen, J. Pavlovitch, M. Papiernik, H. Guillozo, O. Walrant-Debray, C. Pontoux, and M. Garabedian Changes in 1,25-(OH)2D3 Synthesis and Its Receptor Expression in Spleen Cell Subpopulations of Mice Infected with LPBM5 Retrovirus Endocrinology, December 1, 1997; 138(12): 5505 - 5510. [Abstract] [Full Text] [PDF]